CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) shares rallied 8.2% in the last trading session to close at $6.75. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 19.1% gain over the past four weeks.Last month, the company reported robust financial results for the full year ended 2023. The company also made significant progress with the advancement of the dermal and soft tissue filler program toward comme ...

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q4 2023 Earnings Conference Call April 4, 2024 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Greeting and welcome to the CollPlant Biotechnologies Investor Conference Call to discuss Financial Results for the full year and Fourth Quarter of 2023 and Corpora ...

Exhibit 99.1 COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Dermal filler program with AbbVie in clinical phase - Regenerative breast implant program large-animal study underway to evaluate commercial-size implants with topline data expected in Q4 - Ends 2023 with $26.7 million in cash and cash equivalents - Conference call to be held on Thursday, April 4, 2024 at 10:00 a.m. U.S. EDT – REHOVOT, Israel, April 4, 2024 – CollPlant Biotechnologies (Nasdaq: CLG ...

OR Number of outstanding shares of each of the issuer's classes of capital or common stock as of December 31, 2023: 11,452,672 ordinary shares. If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act of 1934. Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. Indicate by check m ...

Dermal filler program with AbbVie in clinical phase Regenerative breast implant program large-animal study underway to evaluate commercial-size implants with topline data expected in Q4 Ends 2023 with $26.7 million in cash and cash equivalents Conference call to be held on Thursday, April 4, 2024 at 10:00 a.m. U.S. EDT  REHOVOT, Israel, April 4, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products base ...

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q3 2023 Earnings Conference Call November 29, 2023 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings. And welcome to the CollPlant Biotechnologies Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is bein ...

● Received a $10 million milestone payment in the third quarter from partner, AbbVie Inc., for achieving a major milestone in the second quarter in accordance with the strategic collaboration agreement related to the clinical-phase dermal filler product candidate Exhibit 99.1 CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023 ● Company is preparing to launch large-animal study with a commercial size breast implant by year-end ● Cash and cash equivalents totaled $29 million as of Se ...

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q2 2023 Earnings Conference Call August 24, 2023 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Ben Haynor - Alliance Global Partners Operator Welcome to the CollPlant Biotechnologies Investor Conference Call to discuss Financial Results for the Second Quarter of 202 ...

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q1 2023 Earnings Conference Call May 24, 2023 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants Ben Haynor - Alliance Global Partners Swayampakula Ramakanth - H.C. Wainwright Operator Welcome to the CollPlant Biotechnologies Investor Conference Call to discuss Financial Results for the First Quarter of 2023 and Corporate Updates. I'd now like to turn the call over to you ...

Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and it ...